Large Volume Wearable Injectors Market (3rd Edition), 2017-2027
NEW YORK, Feb. 23, 2017 /PRNewswire/ -- Drug delivery systems optimized to provide flexibility in dosing regimen, reduce the number of hospital visits, decrease dependence on healthcare professionals and enhance adherence to the therapeutic regimen have become the preferred choice of drug administration. The large scale adoption of prefilled syringes, the first ready-to-use injection device to be marketed, demonstrated the growing interest in the concept of such convenient drug delivery systems. In addition, several pen-injectors and autoinjectors have witnessed an impressive growth in the recent past. However, these hand-held devices are only capable of administering drugs with dosing volume close to 1 ml. With over 900 biologics being developed (most of these are highly viscous and are required to be delivered in volumes greater than 1 ml), there is a growing demand for self-administration devices than can overcome this unmet need.
Read the full report: http://www.reportlinker.com/p04719478-summary/view-report.html
Large volume wearable injectors, an advanced version of the existing self-injection devices, are expected to gather interest from a wide customer base. In fact, there are a number of such injectors commercially available for delivery of insulin. OmniPod, from Insulet Corporation, is a very well-known device that has generated significant year-on-year revenue growth. However, it is worth highlighting that till date only one large volume wearable injector (SmartDose Electronic Wearable Injector) has been approved for administration of a non-insulin biologic. Despite the uncertainties related to the device development and approval, many companies are investing their time, money and resources to develop these novel devices. In addition to the publically known programs, pharma companies have many undisclosed programs that are likely to provide the necessary growth impetus in the long term.
It is worth noting that the VC community has demonstrated significant interest in funding projects related to such wearable injectors. These investments are expected to drive further innovation and lead to the introduction of novel device candidates in the industry. Quite recently, in January 2017, scPharmaceuticals closed a series B investment round worth USD 45.6 million. The company intends to use the funding to bring Furoscix and the sc2Wear Infusor to the market in the US. Earlier, in July 2016, SteadyMed Therapeutics raised USD 32 million in a private placement round financed by Deerfield Capital Management, Federated Investors and OrbiMed. In September 2015, CeQur completed a USD 100 million Venture (Series C) financing round, which was led by Woodford Investment Management, Arthurian Life Sciences, Endeavour Vision, VI Partners and Schroders.
Several partnerships have also been inked in this domain in the last few years. Most of these are focused on the development / commercialization of a variety of wearable injectors. Such partnerships are important for technological integration, supply of devices and also facilitate the conduct of clinical trials related to drug-device combination products. We believe that the device developers will continue to strive to introduce unique and user-friendly features into their proprietary range of devices. The upgradation of existing devices to more competent / next generation devices will serve as a key driver of immediate near-term growth.
SCOPE OF THE REPORTThe "Large Volume Wearable Injectors Market (3rd Edition), 2017-2027" report features an extensive study of the current landscape and the likely future evolution of this category of drug delivery devices over the next ten years. With the increasing incidence of chronic and lifestyle-related diseases across the globe, the demand for efficient drug delivery systems is growing at a rapid pace. In order to simplify the process of drug delivery, eliminate costs and reduce the incidence of needlestick injuries, the pharmaceutical industry has shifted its focus towards the development of self-injection devices for parenteral drugs / therapies. This report specifically lays emphasis on the emergence of such patient-centric, convenient, cost-effective and user-friendly wearable injectors that are capable of administering large volumes of a drug subcutaneously in a home-care setting.
It is worth noting that the concept behind such injectors is being widely employed for the delivery of insulin. Over 15 such unique series of injectors (excluding variants) have already entered the market. On the other hand, there is only one large volume wearable injector (mentioned above) approved for the administration of a non-insulin biologic in the US. However, with a variety of biologics under investigation, we believe that device developers have a significant opportunity waiting to be tapped. The field is likely to pick up momentum in the next few years. In fact, an increase in the partnerships and investment activities demonstrate that the market is geared towards significant growth in the mid to long term.
One of the key objectives outlined for the study was to evaluate the future potential of the ongoing development programs of both big and small firms. Amongst other elements, the report elaborates on the following areas:
- An overview of the current market landscape in terms of the key players involved, development status of pipeline products (marketed / under development), type of dose (bolus / continuous / both), usability (disposable / reusable) and key indications. - Detailed profiles of large volume wearable devices that are being developed for the delivery of biologics (including insulin), highlighting their key features, current status of development, recent developments and associated collaborations.- An exhaustive review of over 300 biologics, which are potential candidates for delivery using large volume wearable injectors. The molecules / therapies have been categorized into most-likely, likely and less-likely candidates for administration using large volume wearable injectors. This categorization is based on various parameters including recommended volume, route of administration, frequency of the dose, standard / weight based dose and the chronicity of target indication.- Comprehensive case studies on drugs that are being evaluated for delivery via large volume wearable injectors, highlighting their specifications, mechanisms of action, current status of development, sales, respective dosages and any other recent developments.- An illustrative grid representation of the devices based on the category of device (insulin / non-insulin biologic), type of dose and type of device (infusion pump / patch pump). In addition, the report includes an insightful 2 X 2 matrix analysis, highlighting the positioning of the devices based on product competitiveness and supplier power. - A discussion on the key drivers and challenges, in terms of the strengths, weaknesses, opportunities and threats (SWOT), which are likely to impact the future growth of this upcoming area.
The study provides a detailed market forecast and opportunity analysis for the period between 2017 and 2027. The research, analysis and insights presented in this report include potential sales of the drug-device combinations that are being evaluated and are anticipated to enter the market in the next few years. To add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base and optimistic scenarios. It is worth noting that, although the market of insulin delivery devices is relatively more mature, we have included a high-level opportunity analysis on the large volume wearable injectors being developed for delivery of insulin as well.
Our opinions and insights presented in this study were influenced by discussions conducted with several experts in this area. Specifically, we solicited the opinions of senior representatives including Menachem Zucker (VP and Chief Scientist, Elcam Medical), Michael Hooven (CEO, Enable Injections), Ben Moga (President, Ratio Drug Delivery), Pieter Muntendam (President and CEO, scPharmaceuticals), Graham Reynolds, (VP and GM, Biologics, West Pharmaceutical Services) and Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. The financial figures mentioned in this report are in USD, unless otherwise specified.
RESEARCH METHODOLOGYMost of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information. The secondary sources of information include
- Annual reports- Investor presentations- SEC filings- Industry databases- News releases from company websites- Government policy documents- Industry analysts' views
While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
CHAPTER OUTLINES Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on the likely evolution of the large volume wearable injectors market.
Chapter 3 provides a general introduction to the market and highlights the growing demand for self-administration injection devices. The chapter lays emphasis on the need for such devices driven by the rising incidence of chronic diseases and emergency cases reported per day. Subsequently, it covers the different types of self-injection devices available in the market, highlighting their advantages. This section also features a brief discussion on the concerns related to needlestick injuries and emphasizes the growing preference for safe and easy-to-use devices.
Chapter 4 presents two separate lists of the large volume wearable injectors for insulin and the other biologics. In addition, the chapter includes a detailed analysis of both these lists based on the products' status of development, device category (infusion pump / patch pump), type of dose (bolus / continuous) and the capacity of each device. Specifically for insulin delivery devices, we have identified whether the device is equipped with continuous glucose monitoring (CGM) monitoring or not.
Chapter 5 presents key takeaways from the market landscape of this emerging field. It features a comparison of product competitiveness and supplier power of each device in the form of a 2 x 2 matrix. In addition, the chapter includes a grid based representation of devices based on the target indication, status of development, type of dose (continuous / bolus / both) and type of device (patch pump / infusion pump). The chapter also provides an analysis of the patents granted / filed in this space over the last three years.
Chapter 6 presents detailed profiles on the large volume wearable injectors being developed for biologics / drugs other than insulin. The profiles include information about the developer of the device, device specifications and features, advantages, current status of development and related collaborations. We have presented such insights on 10 devices capable of delivering large dosage volumes.
Chapter 7 is focused on the devices developed / being developed for the administration of insulin. It presents information on diabetes, the most popular target indication, including information on its epidemiology and the evolution of insulin-delivery systems. Additionally, it includes detailed profiles on some of the large volume wearable devices developed / being developed for the delivery of insulin. Each profile covers information on the device developer, device specifications, advantages and the associated developments. The chapter also includes a social media analysis highlighting the popularity of these devices in the industry.
Chapter 8 provides detailed case studies on the drugs / therapies that are currently being evaluated with the devices mentioned in chapter 4. Each case study includes drug / therapy specifications, respective mechanisms of action, current status of development, information on the sales of each product, dosage and recent developments.
Chapter 9 presents a list of candidates (marketed / pipeline) that have the potential to be administered using large volume wearable injectors in the future. The likelihood of delivery of a molecule was estimated based on the volume of dose, mode of administration, frequency of administration, standard / weight-based dose and the chronicity of the target indication.
Chapter 10 provides projections of the future opportunity of the large volume wearable injectors market for biologics till 2027. It highlights the market size of such injectors (in terms of value) and the number of units that are likely to be sold within the forecast time period. We have clearly laid out the forecast methodology along with the key assumptions that were taken into consideration for estimating the market size.
Chapter 11 includes comprehensive profiles of the key companies that are active in this market. We have profiled companies (presented in an alphabetical order) developing devices for administration of insulin / other biologics. Each company profile includes a company overview, details on its financial performance, product portfolio and collaborations.
Chapter 12 provides a SWOT analysis, highlighting strategic insights on major factors that have contributed to the growth of the market, while highlighting the weaknesses and threats that are likely to have an impact on its future.
Chapter 13 summarizes the overall report and provides a recap of the key takeaways from the study. It also presents our independent opinion on the future of large volume wearable injectors market based on the research and analysis described in the previous chapters.
Chapter 14 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the insights provided to us by Menachem Zucker (VP and Chief Scientist, Elcam Medical), Michael Hooven (CEO, Enable Injections), Ben Moga (President, Ratio Drug Delivery), Pieter Muntendam (President and CEO, scPharmaceuticals), Graham Reynolds, (VP and GM, Biologics, West Pharmaceutical Services) and Tiffany H. Burke (Director, Global Communications, West Pharmaceutical Services).
Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures presented in the report.
Chapter 16 is an appendix, which provides a list of companies and organizations mentioned in this report.
EXAMPLE HIGHLIGHTS1. There are over 50 different large volume wearable injectors (including variants) that are either commercialized or are under development. Of these, around 60% are for delivery of insulin and the rest are for delivery of other biologics. Of the devices being developed for delivery of non-insulin biologics, SmartDose Electronic Wearable Injector (by West Pharmaceutical Services) has already received approval by the USFDA for delivery of Repatha.
2. There are several other known references of drug-device combinations that are being evaluated in clinical studies; examples include SteadyMed Therapeutics' PatchPump (with Treprostinil and Ketorolac), NeuroDerm's CRONO ND (with NDO612 and NDO712), Roche's Single-use injection device (with Herceptin) and scPharmaceuticals's scWear Infusor (with Ceftriaxone and Furosemide).
3. The commercially available insulin-based large volume wearable injectors can accommodate volumes of up to 5 ml. OmniPod, from Insulet Corporation, is a very well-known device that has generated significant year-on-year revenue growth. However, with improved design, several devices with capacity of holding up to 20 ml drug are being developed for delivery of biologics. In fact, over 50% of the devices that we identified for administration of non-insulin biologics have the capability of carrying 5-20 ml drug while 16% of these devices can hold over 20 ml drug.
4. Our analysis suggests that close to 100 biologics (marketed / under development) are suited for delivery via large volume wearable injectors and are likely to be evaluated in different drug-device combinations in the near future. These biologics (full list available in the main report) are designed for treatment of chronic conditions, which require frequent dosing, and are not currently available in suitable self-administration systems. We believe that some of these drugs, if tested and approved with large volume wearable injectors, are likely to make a substantial contribution to the market's evolution in the mid-long term.
5. Innovation in the field is primarily being driven by start-ups / small companies; examples of firms working for delivery of non-insulin biologics include (in alphabetical order) Elcam Drug Delivery Systems, Enable Injections, NeuroDerm, scPharmaceuticals, Sensile Medical. Notable examples of start-ups that have taken initiatives for delivery of insulin include Cellnovo, CeQur, Debiotech, PicoSulin, SOOIL and ViCentra. In addition, a number of large companies are making notable contribution in this field; prominent players include Becton Dickinson, Johnson & Johnson, Medtronic, Roche and West Pharmaceutical Services.
6. Several other companies engaged in this domain have reported positive clinical outcomes of their drug-device combinations. scPharmaceuticals is expecting the commercial launch of its two product candidates for the drugs furosemide and cephalosporin in 2017 / 18. In addition, Neuroderm and SteadyMed Therapeutics are also hopeful of making their products commercially available in the near future. At the same time, insulin delivery devices, such as OmniPod, are now also being explored for the delivery of non-insulin drugs, such as the gonadotropin-releasing hormone developed by Ferring Pharmaceuticals.
7. The overall market for large volume wearable injectors is likely to grow at an aggressive rate of over 150%. We believe that OmniPod will continue to lead the market for insulin delivery. However, majority of the growth is likely to come from drug-device combinations under trials for non-insulin biologics. In our base scenario, we have predicted that the annual sales volume of such devices could be over 40 million units by 2027.
Read the full report: http://www.reportlinker.com/p04719478-summary/view-report.html
About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
__________________________Contact Clare: email@example.comUS: (339)-368-6001Intl: +1 339-368-6001
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/large-volume-wearable-injectors-market-3rd-edition-2017-2027-300413116.html